KR101764991B1 - 특히 높은 her2 단백질 농도를 갖는 신생물성 질환의 치료를 위한 타목시펜 유도체 - Google Patents

특히 높은 her2 단백질 농도를 갖는 신생물성 질환의 치료를 위한 타목시펜 유도체 Download PDF

Info

Publication number
KR101764991B1
KR101764991B1 KR1020157030376A KR20157030376A KR101764991B1 KR 101764991 B1 KR101764991 B1 KR 101764991B1 KR 1020157030376 A KR1020157030376 A KR 1020157030376A KR 20157030376 A KR20157030376 A KR 20157030376A KR 101764991 B1 KR101764991 B1 KR 101764991B1
Authority
KR
South Korea
Prior art keywords
general formula
tamoxifen
tax
derivative
her2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020157030376A
Other languages
English (en)
Korean (ko)
Other versions
KR20150144756A (ko
Inventor
지리 네우질
잔 스투르사
루카스 워너
Original Assignee
스마트 브레인 에스.알.오.
바이오테크놀로지키 우스타브 에이브이 씨알, 브이.브이.아이.
지리 네우질
케이케이씨쥐 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50677895&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101764991(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CZ2013-308A external-priority patent/CZ304553B6/cs
Priority claimed from CZ2014-66A external-priority patent/CZ305571B6/cs
Application filed by 스마트 브레인 에스.알.오., 바이오테크놀로지키 우스타브 에이브이 씨알, 브이.브이.아이., 지리 네우질, 케이케이씨쥐 아게 filed Critical 스마트 브레인 에스.알.오.
Publication of KR20150144756A publication Critical patent/KR20150144756A/ko
Application granted granted Critical
Publication of KR101764991B1 publication Critical patent/KR101764991B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5456—Arylalkanephosphonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5449—Polyphosphonium compounds
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/0008—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain
    • C09B23/0025—Methine or polymethine dyes, e.g. cyanine dyes substituted on the polymethine chain the substituent being bound through an oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B23/00—Methine or polymethine dyes, e.g. cyanine dyes
    • C09B23/14—Styryl dyes
    • C09B23/141—Bis styryl dyes containing two radicals C6H5-CH=CH-
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00—Dyes not provided for by a single group of this subclass
    • C09B69/001—Dyes containing an onium group attached to the dye skeleton via a bridge
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
    • C09B69/00—Dyes not provided for by a single group of this subclass
    • C09B69/008—Dyes containing a substituent, which contains a silicium atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epidemiology (AREA)
KR1020157030376A 2013-04-24 2014-04-07 특히 높은 her2 단백질 농도를 갖는 신생물성 질환의 치료를 위한 타목시펜 유도체 Expired - Fee Related KR101764991B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CZPV2013-308 2013-04-24
CZ2013-308A CZ304553B6 (cs) 2013-04-24 2013-04-24 Deriváty tamoxifenu účinné proti nádorům, zejména s vyšší hladinou proteinu HER2
CZ2014-66A CZ305571B6 (cs) 2014-01-29 2014-01-29 Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2
CZPV2014-66 2014-01-29
PCT/CZ2014/000035 WO2014173374A1 (en) 2013-04-24 2014-04-07 Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level

Publications (2)

Publication Number Publication Date
KR20150144756A KR20150144756A (ko) 2015-12-28
KR101764991B1 true KR101764991B1 (ko) 2017-08-10

Family

ID=50677895

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157030376A Expired - Fee Related KR101764991B1 (ko) 2013-04-24 2014-04-07 특히 높은 her2 단백질 농도를 갖는 신생물성 질환의 치료를 위한 타목시펜 유도체

Country Status (21)

Country Link
US (1) US9896466B2 (enExample)
EP (1) EP2989110B1 (enExample)
JP (1) JP6375091B2 (enExample)
KR (1) KR101764991B1 (enExample)
CN (1) CN105452265B (enExample)
AU (1) AU2014256546B2 (enExample)
CA (1) CA2909994C (enExample)
CY (1) CY1120821T1 (enExample)
DK (1) DK2989110T3 (enExample)
EA (1) EA029881B1 (enExample)
ES (1) ES2699099T3 (enExample)
GE (1) GEP20186868B (enExample)
HR (1) HRP20181872T1 (enExample)
HU (1) HUE042239T2 (enExample)
MD (1) MD4626C1 (enExample)
NZ (1) NZ713589A (enExample)
PL (1) PL2989110T3 (enExample)
PT (1) PT2989110T (enExample)
SI (1) SI2989110T1 (enExample)
UA (1) UA116469C2 (enExample)
WO (1) WO2014173374A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA033155B1 (ru) * 2015-07-03 2019-09-30 Байер Кропсайенс Акциенгезельшафт Гербицидно активные производные n-(тетразол-5-ил)арилкарбоксамида
US10556874B2 (en) * 2015-07-03 2020-02-11 Bayer Cropscience Aktiengesellschaft N-(1,3,4-oxadiazol-2-yl)aryl carboxamide derivatives with herbicidal action
CN110294788A (zh) * 2016-07-12 2019-10-01 冰洲石生物科技公司 新的化合物及其用途
JP7100019B2 (ja) 2016-08-19 2022-07-12 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 選択的エストロゲン受容体モジュレーター（ｓｅｒｍ）は、光受容体の変性に対する保護を付与する
EP3330274A1 (en) * 2016-12-01 2018-06-06 Springtide Ventures s.r.o. Compounds for treatment of senescence-related disorders
CA3060509A1 (en) 2017-04-21 2018-10-25 Federica Sotgia Targeting hypoxic cancer stem cells (cscs) with doxycycline: implications for improving anti-angiogenic therapy
WO2018195434A1 (en) 2017-04-21 2018-10-25 Lisanti Michael P Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
BR112019024264A2 (pt) 2017-05-19 2020-06-02 Lunella Biotech, Inc. Antimitoscinas: inibidores direcionados da biogênese mitoconcrial para erradicação de células-tronco de câncer
EP3700512A4 (en) 2017-10-24 2021-08-11 Lunella Biotech, Inc. MITOFLAVOSCINE: TARGETING FLAVINAL ENZYMES ELIMINATES CANCER STEM CELLS (CSCS) BY INHIBITING MITOCHONDRIAL BREATHING
RU2020120686A (ru) 2017-11-24 2021-12-24 Лунелла Байотек, Инк. Соединения производных трифенилфосфония для эрадикации раковых стволовых клеток
WO2019108729A1 (en) 2017-12-01 2019-06-06 Lunella Biotech, Inc. Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
WO2019113210A1 (en) 2017-12-05 2019-06-13 Anthos Partners, Lp Phosphonium-based ionic drug conjugates
WO2019126179A1 (en) 2017-12-20 2019-06-27 Lunella Biotech, Inc. Targeting mitochondrial fission through mdivi-1 derivatives
JP7586835B2 (ja) * 2019-04-16 2024-11-19 ルネラ・バイオテック・インコーポレーテッド ミトコンドリア標的化及び抗癌治療のためのアルキルｔｐｐ化合物
EP3753944A1 (en) 2019-06-17 2020-12-23 Institute Of Biotechnology Cas, V.V.I. 3,5-bis(phenyl)-1h-heteroaryl derivatives as medicaments

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2092996A1 (en) * 1990-10-01 1992-04-02 David Yang High affinity tamoxifen derivatives and uses thereof
JP3635708B2 (ja) * 1995-03-06 2005-04-06 出光興産株式会社 有機エレクトロルミネッセンス素子
TWI309571B (en) * 2002-12-31 2009-05-11 Ind Tech Res Inst Delivery carrier for targeting cells haring over-expressed estrogen
IL173807A (en) * 2003-08-22 2014-02-27 Antipodean Pharmaceuticals Inc Antioxidant amphiphilic compounds, histoquinone history and pharmaceutical preparations containing them
US20070225255A1 (en) * 2004-07-13 2007-09-27 Eleonore Frohlich Use of Mitochondrially Targeted Antioxidant in the Treatment of Liver Diseases and Epithelial Cancers
KR101642157B1 (ko) * 2008-03-14 2016-07-22 스티븐 존 랄프 미토콘드리아로 전달되는 항암 화합물
EP2419095A4 (en) * 2009-04-17 2012-12-05 Colby Pharmaceutical Company PHARMACEUTICALLY ACTIVE COMPOSITIONS COMPRISING OXIDATIVE STRESS MODULATORS (OSM), NOVEL CHEMICAL ENTITIES, COMPOSITIONS AND USES
WO2011129837A1 (en) * 2010-04-16 2011-10-20 Olema Pharmaceuticals, Inc. Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
J. Biol. Chem., 2006, Vol.281, pp.10143-10152(2006.01.12.)
Mitocondrion, 2010, Vol.10, pp.670-681(2010.07.01.)
PNAS, 2003, Vol.100, pp.5407-5412(2003.04.29.)

Also Published As

Publication number Publication date
JP6375091B2 (ja) 2018-08-15
CA2909994A1 (en) 2014-10-30
EP2989110A1 (en) 2016-03-02
CN105452265A (zh) 2016-03-30
PT2989110T (pt) 2018-11-15
EP2989110B1 (en) 2018-08-08
DK2989110T3 (en) 2018-12-03
HK1216317A1 (zh) 2016-11-04
MD20150117A2 (ro) 2016-08-31
EA029881B1 (ru) 2018-05-31
HRP20181872T1 (hr) 2019-02-08
ES2699099T3 (es) 2019-02-07
SI2989110T1 (sl) 2019-01-31
HUE042239T2 (hu) 2019-06-28
UA116469C2 (uk) 2018-03-26
GEP20186868B (en) 2018-06-25
NZ713589A (en) 2017-12-22
US9896466B2 (en) 2018-02-20
PL2989110T3 (pl) 2019-03-29
MD4626B1 (ro) 2019-04-30
CY1120821T1 (el) 2019-12-11
JP2016522179A (ja) 2016-07-28
CA2909994C (en) 2018-06-26
AU2014256546A1 (en) 2015-11-12
EA201591918A1 (ru) 2016-02-29
MD4626C1 (ro) 2019-11-30
CN105452265B (zh) 2017-05-10
KR20150144756A (ko) 2015-12-28
WO2014173374A1 (en) 2014-10-30
US20160075726A1 (en) 2016-03-17
AU2014256546B2 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
KR101764991B1 (ko) 특히 높은 her2 단백질 농도를 갖는 신생물성 질환의 치료를 위한 타목시펜 유도체
EP3706737B1 (en) Ash1l inhibitors and methods of treatment therewith
Kumbhare et al. Synthesis and biological evaluation of novel Mannich bases of 2-arylimidazo [2, 1-b] benzothiazoles as potential anti-cancer agents
JP2016522179A5 (enExample)
Singh et al. A family of silatrane‐armed triazole‐encapped salicylaldehyde‐derived Schiff bases: Synthesis, spectral analysis, and antimicrobial and quantum chemical evaluation
Yang et al. A novel drug prejudice scaffold-imidazopyridine-conjugate can promote cell death in a colorectal cancer model by binding to β-catenin and suppressing the Wnt signaling pathway
Liu et al. Design and biological features of platinum (II) complexes with 3-hydroxy-3-(Trifluoromethyl) cyclobutane-1, 1-Dicarboxylate as a leaving ligand
WO2011124087A1 (zh) 噁二唑基哌嗪衍生物及其用途
Vosooghi et al. Design, synthesis, docking study and cytotoxic activity evaluation of some novel letrozole analogs
CN104592091B (zh) 一种含吲哚乙酸核心结构的化合物及其应用
CA3045365C (en) Compounds for treatment of senescence-related disorders
WO2019236957A1 (en) Prc1 inhibitors and methods of treatment therewith
CN109328062A (zh) 小分子活性氧簇诱导剂和线粒体活性抑制剂
Özdaş et al. Targeting of nucleo‑cytoplasmic transport factor exportin 1 in malignancy
CZ304553B6 (cs) Deriváty tamoxifenu účinné proti nádorům, zejména s vyšší hladinou proteinu HER2
WO2018017589A1 (en) Compounds for targeting cancer stem cells
HK1216317B (en) Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level
CZ201466A3 (cs) Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2
US10577387B1 (en) Platinum (II) complexes containing N-heterocyclic carbene ligand and pincer ligands, synthesis, and their applications in cancer treatment
Usman et al. A novel biocompatible formate bridged 1D-Cu (ii) coordination polymer induces apoptosis selectively in human lung adenocarcinoma (A549) cells
EP2909171B1 (fr) Composés 3,4-bis(catéchol)pyrrole n-substitués, leur préparation et utilisation dans le traitement du cancer
Adegbulugbe Synthesis and Evaluation of Tetramethoxy Stilbenes Related to Combretastatin A-4 as Potential Anticancer Agents
CN117777154A (zh) 一种Hsp27抑制剂及其制备方法和药学上的应用
WO2021064175A1 (en) Compounds for preventing migration of cancer cells

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240729

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240729